Company eyes shift to high-value-added injectable drugs, Yoshida says Towa gained a U.S. sales network from the 2020 acquisition of a Spanish drugmaker.
Company eyes shift to high-value-added injectable drugs, Yoshida says Towa gained a U.S. sales network from the 2020 acquisition of a Spanish drugmaker. (Photo by Nikkei) OSAKA -- Towa Pharmaceutical plans to start exporting generic injectable drugs to the U.S. as early as 2028, with the company seeking to leverage its advanced quality control capabilities to gain a foothold in the competitive American market.